| Primary | Change From Baseline in Glycated Haemoglobin (HbA1c) (Week 52) | Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. Percentage point refers to arithmetic difference between two percentages. | Full Analysis Set (FAS) which comprised all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | Percentage point of HbA1c | | Baseline (week 0), week 52 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
| | | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG000-1.5± 1.3
- OG001-1.9± 1.3
- OG002-2.1± 1.4
|
|
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| Treatment policy estimand | ANCOVA | | 0.0006 | Unadjusted two-sided p-value for test of no difference. | Treatment difference | -0.27 | | | 2-Sided | 95 | -0.42 | -0.12 | | | | | Superiority | Change from baseline was analyzed using an ANCOVA model with treatment, strata and region as categorical fixed effects and baseline value as covariate for each of the 1000 imputed complete datasets,and pooled by Rubin's rule to draw inference. | |
|
| Secondary | Change From Baseline in Body Weight (Week 52) | Change from baseline (week 0) in body weight was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. | FAS which comprised all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | Kilogram (Kg) | | Baseline (week 0), week 52 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Change From Baseline in HbA1c (Week 68) | Change from baseline (week 0) in HbA1c was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. Percentage point refers to arithmetic difference between two percentages. | FAS which comprised all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | Percentage point of HbA1c | | Baseline (week 0), week 68 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | |
|
| Secondary | Change From Week 12 in HbA1c (Week 52) | Change in HbA1c was evaluated from week 12 to week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. Percentage point refers to arithmetic difference between two percentages. | FAS which comprised all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | Percentage point of HbA1c | | Week 12, Week 52 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | |
|
| Secondary | Change From Baseline in Fasting Plasma Glucose (FPG) (Week 52) | Change from baseline (week 0) in fasting plasma glucose (FPG) was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. | FAS which comprised all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | millimole per litre (mmol/L) | | Baseline (week 0), week 52 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | |
|
| Secondary | Change From Baseline in FPG (Week 68) | Change from baseline (week 0) in FPG was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. | FAS which comprised all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | mmol/L | | Baseline (week 0), week 68 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Percentage of Participants Who Achieved HbA1c Less Than (<) 7.0 (Percent [%]) (Week 52) | Percentage of participants who achieved HbA1c <7.0 % at week 52 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. | FAS which comprised all randomised participants. | Posted | | Number | | Percentage of Participants | | At week 52 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Percentage of Participants Who Achieved HbA1c < 7.0 % (Week 68) | Percentage of participants who achieved HbA1c <7.0 % at week 68 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. | FAS which comprised all randomised participants. | Posted | | Number | | Percentage of Participants | | At week 68 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Percentage of Participants Who Achieved HbA1c Less Than or Equal to (<=) 6.5 % (Week 52) | Percentage of participants who achieved HbA1c <=6.5 % at week 52 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. | FAS which comprised all randomised participants. | Posted | | Number | | Percentage of Participants | | At week 52 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Percentage of Participants Who Achieved HbA1c <= 6.5 % (Week 68) | Percentage of participants who achieved HbA1c <=6.5 % at week 68 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. | FAS which comprised all randomised participants. | Posted | | Number | | Percentage of Participants | | At week 68 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Time to Event Analyses of Rescue Medication | Time to event analyses of rescue medication was evaluated from baseline (week 0) to week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. | FAS which comprised all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Median | Full Range | Weeks | | Baseline (week 0), week 68 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Change From Baseline in Body Weight (Week 68) | Change from baseline (week 0) in body weight was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. | FAS which comprised all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | Kg | | Baseline (week 0), week 68 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Percentage Change From Baseline in Body Weight (Week 52) | Percentage change from baseline (week 0) in body weight was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. | FAS which comprised all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | Percentage change in body weight | | Baseline (week 0), week 52 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | |
|
| Secondary | Percentage Change From Baseline in Body Weight (Week 68) | Percentage change from baseline (week 0) in body weight was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. | FAS which comprised all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | Percentage change in body weight | | Baseline (week 0), week 68 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | |
|
| Secondary | Percentage Change From Week 12 in Body Weight (Week 52) | Percentage change in body weight was evaluated from week 12 to week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. | FAS which comprised all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | Percentage change in body weight | | Week 12, Week 52 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Change From Baseline in Body Mass Index (BMI) (Week 52) | Change from baseline (week 0) in body mass index (BMI) was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. | FAS which comprised all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | kilogram per square metre (kg/m^2) | | Baseline (week 0), week 52 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | |
|
| Secondary | Change From Baseline in BMI (Week 68) | Change from baseline (week 0) in BMI was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. | FAS which comprised all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | kg/m^2 | | Baseline (week 0), week 68 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Change From Baseline in Waist Circumference (Week 52) | Change from baseline (week 0) in waist circumference was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. | FAS which comprised all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | centimetre (cm) | | Baseline (week 0), week 52 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Change From Baseline in Waist Circumference (Week 68) | Change from baseline (week 0) in waist circumference was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. | FAS which comprised all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | cm | | Baseline (week 0), week 68 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Percentage of Participants Who Achieved Weight Loss Greater Than or Equal to (>=) 5 % (Week 52) | Percentage of participants who achieved weight loss >= 5 % at week 52 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. | FAS which comprised all randomised participants. | Posted | | Number | | Percentage of participants | | At week 52 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Percentage of Participants Who Achieved Weight Loss >= 5 % (Week 68) | Percentage of participants who achieved weight loss >= 5 % at week 68 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. | FAS which comprised all randomised participants. | Posted | | Number | | Percentage of participants | | At week 68 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Percentage of Participants Who Achieved Weight Loss >= 10 % (Week 52) | Percentage of participants who achieved weight loss >= 10 % at week 52 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. | FAS which comprised all randomised participants. | Posted | | Number | | Percentage of participants | | At week 52 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Percentage of Participants Who Achieved Weight Loss >= 10 % (Week 68) | Percentage of participants who achieved weight loss >= 10 % at week 68 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. | FAS which comprised all randomised participants. | Posted | | Number | | Percentage of participants | | At week 68 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Change From Baseline in Total Cholesterol (Week 52) | Change from baseline (week 0) in total cholesterol was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. | FAS which comprised all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | mmol/L | | Baseline, Week 52 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Change From Baseline in Total Cholesterol (Week 68) | Change from baseline (week 0) in total cholesterol was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. | FAS which comprised all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | mmol/L | | Baseline, Week 68 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Change From Baseline in Low Density Lipoproteins (LDL) (Week 52) | Change from baseline (week 0) in LDL was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. | FAS which comprised all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | mmol/L | | Baseline, Week 52 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Change From Baseline in LDL (Week 68) | Change from baseline (week 0) in LDL was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. | FAS which comprised all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | mmol/L | | Baseline, Week 68 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Change From Baseline in High Density Lipoproteins (HDL) (Week 52) | Change from baseline (week 0) in HDL was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. | FAS which comprised all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | mmol/L | | Baseline, Week 52 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Change From Baseline in HDL (Week 68) | Change from baseline (week 0) in HDL was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. | FAS which comprised all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | mmol/L | | Baseline, Week 68 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Change From Baseline in Triglycerides (Week 52) | Change from baseline (week 0) in triglycerides was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. | FAS which comprised all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | mmol/L | | Baseline, Week 52 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Change From Baseline in Triglycerides (Week 68) | Change from baseline (week 0) in triglycerides was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. | FAS which comprised all randomised participants. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | mmol/L | | Baseline, Week 68 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Number of Adverse Events | An adverse event (AE) defined as any unfavourable and unintended sign, including an abnormal laboratory finding, symptom or disease (new or exacerbated) temporally associated with the use of an investigational medicinal products (IMP). Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication. | Safety Analysis Set (SAS) which comprised all participants who received at least 1 dose of trial treatment. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Number | | Events | | From baseline (week 0) up to week 73 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg |
|
| Secondary | Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 Milligram Per Decilitre [mg/dL]) or Severe Hypoglycaemic Episodes (Level 3) | Hypoglycaemic episodes were classified according to the American Diabetes Association 2018/ International Hypoglycaemia Study Group 2017, where glycemic criteria for level 2 was < 3.0 mmol/L (54 mg/dL) and level 3 had no specific glucose threshold. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication. | SAS which comprised all participants who received at least 1 dose of trial treatment. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Number | | Count of episodes | | From baseline (week 0) up to week 68 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | |
|
| Secondary | Change From Baseline in Systolic Blood Pressure (Week 52) | Change from baseline (week 0) in systolic blood pressure at week 52 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication. | SAS which comprised all participants who received at least 1 dose of trial treatment. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | millimetres of mercury (mmHg) | | Baseline (week 0), week 52 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Change From Baseline in Systolic Blood Pressure (Week 68) | Change from baseline (week 0) in systolic blood pressure at week 68 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication. | SAS which comprised all participants who received at least 1 dose of trial treatment. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | mmHg | | Baseline (week 0), week 68 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Change From Baseline in Diastolic Blood Pressure (Week 52) | Change from baseline (week 0) in diastolic blood pressure at week 52 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication. | SAS which comprised all participants who received at least 1 dose of trial treatment. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | mmHg | | Baseline (week 0), week 52 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Change From Baseline in Diastolic Blood Pressure (Week 68) | Change from baseline (week 0) in diastolic blood pressure at week 68 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication. | SAS which comprised all participants who received at least 1 dose of trial treatment. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | mmHg | | Baseline (week 0), week 68 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Change From Baseline in Pulse (Week 52) | Change from baseline (week 0) in pulse at week 52 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication. | SAS which comprised all participants who received at least 1 dose of trial treatment. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | beats per minute (beats/min) | | Baseline (week 0), week 52 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|
| Secondary | Change From Baseline in Pulse (Week 68) | Change from baseline (week 0) in pulse at week 68 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication. | SAS which comprised all participants who received at least 1 dose of trial treatment. Overall number of participants analyzed = participants with available data for this outcome measure. | Posted | | Mean | Standard Deviation | beats/min | | Baseline (week 0), week 68 | | | | ID | Title | Description |
|---|
| OG000 | Oral Semaglutide 14 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 68. | | OG001 | Oral Semaglutide 25 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12 and 25 mg from week 12 to week 68. | | OG002 | Oral Semaglutide 50 mg | Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 68: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8, 14 mg from week 8 to 12, 25 mg from week 12 to week 16 and 50 mg from week 16 to week 68. |
|